ENOV (Enovis) Cyclically Adjusted Revenue per Share: $56.04 (As of Mar. 2026)


ENOV Enovis Corp ENOV
64 GF Score
Price $25.75
GF Value $50.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Enovis Cyclically Adjusted Revenue per Share?

Enovis ENOV +2.10% 64 Cyclically Adjusted Revenue per Share is $56.04 as of Mar. 2026. GuruFocus rates ENOV with a GF Score™ of 64/100 and a GF Value™ of $50.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enovis's adjusted revenue per share for the three months ended in Mar. 2026 was $10.280. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $56.04 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Enovis's average Cyclically Adjusted Revenue Growth Rate was -8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -11.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -8.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enovis was 3.20% per year. The lowest was -11.30% per year. And the median was -0.20% per year.

As of today (2026-07-11), Enovis's current stock price is $25.75. Enovis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $56.04. Enovis's Cyclically Adjusted PS Ratio of today is 0.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enovis was 1.03. The lowest was 0.32. And the median was 0.68.


Enovis  (NYSE:ENOV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enovis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=25.75/56.04
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enovis was 1.03. The lowest was 0.32. And the median was 0.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enovis Cyclically Adjusted Revenue per Share Related Terms


Enovis Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Enovis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis Cyclically Adjusted Revenue per Share Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.37 81.46 71.69 62.51 56.89

Enovis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.37 59.57 57.77 56.89 56.04

ENOV vs INSP, PRCT, AHCO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Enovis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enovis Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Enovis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enovis's Cyclically Adjusted PS Ratio falls into.


ENOV
64GF Score
Enovis Corp ENOV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enovis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enovis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.28/330.2130*330.2130
=10.280

Current CPI (Mar. 2026) = 330.2130.

Enovis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 23.341 241.018 31.979
201609 18.680 241.428 25.550
201612 19.750 241.432 27.013
201703 17.779 243.801 24.081
201706 20.523 244.955 27.666
201709 20.418 246.819 27.317
201712 -11.813 246.524 -15.823
201803 21.299 249.554 28.183
201806 13.682 251.989 17.929
201809 13.271 252.439 17.360
201812 14.645 251.233 19.249
201903 15.344 254.202 19.932
201906 19.906 256.143 25.662
201909 18.530 256.759 23.831
201912 18.990 256.974 24.402
202003 17.311 258.115 22.146
202006 13.609 257.797 17.432
202009 17.509 260.280 22.213
202012 -24.591 260.474 -31.175
202103 18.605 264.877 23.194
202106 6.943 271.696 8.438
202109 6.787 274.310 8.170
202112 7.425 278.802 8.794
202203 6.969 287.504 8.004
202206 7.247 296.311 8.076
202209 7.090 296.808 7.888
202212 7.543 296.797 8.392
202303 7.476 301.836 8.179
202306 7.861 305.109 8.508
202309 7.654 307.789 8.212
202312 8.335 306.746 8.973
202403 9.440 312.332 9.980
202406 9.573 314.175 10.062
202409 9.076 315.301 9.505
202412 10.034 315.605 10.498
202503 9.840 319.799 10.160
202506 9.881 322.561 10.115
202509 9.602 324.800 9.762
202512 10.068 324.054 10.259
202603 10.280 330.213 10.280

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $56.04 mean?
Enovis (ENOV) has a Cyclically Adjusted Revenue per Share of $56.04 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Enovis and its competitors.
Is Enovis' Cyclically Adjusted Revenue per Share too high?
Enovis' current Cyclically Adjusted Revenue per Share is $56.04. Overall, Enovis has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' Cyclically Adjusted Revenue per Share compare to INSP and PRCT?
Enovis' Cyclically Adjusted Revenue per Share of $56.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Enovis and its competitors. Enovis's current Cyclically Adjusted Revenue per Share is $56.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $50.15, compared to a current price of $25.75 — trading 48.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $56.04. Enovis' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Enovis (ENOV), the current Cyclically Adjusted Revenue per Share is $56.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (ENOV) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of $25.75 is trading 48.7% below its estimated GF Value™ of $50.15. GuruFocus considers Enovis to be Possible Value Trap.

Key valuation signals for ENOV:

  • Cyclically Adjusted Revenue per Share: $56.04
  • GF Value™: $50.15 vs. price of $25.75 (48.7% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
64GF Score

Get the complete analysis for ENOV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.75
Price
$50.15
GF Value